At a Glance
- Tasks: Lead the execution of a Phase 2 clinical programme for rare diseases.
- Company: Award-winning pharmaceutical company driving change in rare diseases.
- Benefits: Equity/deferred payment initially, with potential for full-time paid role post-funding.
- Other info: Join a dynamic team in a fast-paced, entrepreneurial environment.
- Why this job: Make a real impact in the field of rare diseases and shape clinical strategies.
- Qualifications: MD/PhD with Phase 2 clinical development experience and strong regulatory insight.
The predicted salary is between 80000 - 100000 £ per year.
Our client is an award-winning entrepreneurial pharmaceutical company working to drive change in rare diseases. They are seeking an experienced Clinical Director to lead the finalisation and execution of a Phase 2 clinical programme.
The role holder will:
- Finalise Phase 2 protocol, endpoints, and regulatory strategy
- Align clinical documentation to investor- and regulator-ready standard
- Support fundraising and grant applications
- Lead CRO selection and trial readiness
The role demands an MD/PhD with Phase 2 clinical development experience. Strong regulatory insight (FDA/EMA) is required; rare disease expertise is desirable. The role holder must be hands-on, detail-oriented, and execution-focused and comfortable operating in a lean, fast-moving environment.
The role is initially part-time (equity/deferred payment), moving to paid role post-funding with potential to scale to full-time.
Clinical Director Rare Diseases employer: george james ltd
As an award-winning entrepreneurial pharmaceutical company, we pride ourselves on fostering a dynamic and innovative work culture that empowers our employees to make a real impact in the field of rare diseases. With flexible working arrangements and a commitment to professional growth, we offer unique opportunities for career advancement while supporting meaningful projects that drive change. Join us in a collaborative environment where your expertise will be valued and your contributions can lead to significant advancements in healthcare.
